ClinicalTrials.Veeva

Menu
S

Sanatorio Parque | Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MK-1084
MK-6482-034
Belzutifan
Zanzalintinib
MK-6482
MK-3475A±MK-1084
Pembrolizumab
Sotatercept
MK-7962-005

Parent organization

This site is a part of Sanatorio Parque

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).A standard (usual) treatment for certain people with RCC is belzuti...

Enrolling
Carcinoma, Renal Cell
Drug: Placebo
Drug: Zanzalintinib
Locations recently updated

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation...

Enrolling
Rectal Adenocarcinoma
Colon Adenocarcinoma
Drug: Leucovorin/levofolinate calcium
Drug: 5-Fluorouracil

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood t...

Enrolling
Pulmonary Arterial Hypertension
Biological: Sotatercept

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in partici...

Enrolling
Advanced Solid Tumors
Biological: cetuximab
Drug: carboplatin

This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus...

Enrolling
Non-small Cell Lung Cancer
Drug: Calderasib
Drug: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Acceleron Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems